These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 36178566)

  • 21. Efficacy, Usability, and Acceptability of a Chatbot for Promoting COVID-19 Vaccination in Unvaccinated or Booster-Hesitant Young Adults: Pre-Post Pilot Study.
    Luk TT; Lui JHT; Wang MP
    J Med Internet Res; 2022 Oct; 24(10):e39063. PubMed ID: 36179132
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Prevalence of COVID-19 Vaccination and Vaccine Hesitancy in Pregnant Women: An Internet-based Cross-sectional Study in Japan.
    Hosokawa Y; Okawa S; Hori A; Morisaki N; Takahashi Y; Fujiwara T; Nakayama SF; Hamada H; Satoh T; Tabuchi T
    J Epidemiol; 2022 Apr; 32(4):188-194. PubMed ID: 35095091
    [TBL] [Abstract][Full Text] [Related]  

  • 23. COVID-19 vaccination rate and willingness of an additional dose among inflammatory bowel disease patients receiving biologic therapy: Fearless and with desire.
    Ramos L; Carrillo-Palau M; Alonso-Abreu I; Reygosa C; Hernández-Alvarez N; Amaral C; Hernández A; Benítez-Zafra F; Pérez-González F; Quintana-Díaz H; Hernandez-Guerra M
    Gastroenterol Hepatol; 2023 Apr; 46(4):255-260. PubMed ID: 35609791
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adverse events of a third dose of BNT162b2 mRNA COVID-19 vaccine among Korean healthcare workers.
    Lee DY; Kang DY; Kim E; Lee SJ; Baek JH; Lee JS; Park MY; Im JH
    Medicine (Baltimore); 2023 Mar; 102(11):e33236. PubMed ID: 36930126
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Misconceptions Drive COVID-19 Vaccine Hesistancy in Individuals with Inflammatory Bowel Disease.
    Zhang E; Gupta A; Al-Ani A; Macrae FA; Leong RW; Christensen B
    Can J Gastroenterol Hepatol; 2022; 2022():4527844. PubMed ID: 36124090
    [TBL] [Abstract][Full Text] [Related]  

  • 26. COVID-19 Vaccine Is Effective in Inflammatory Bowel Disease Patients and Is Not Associated With Disease Exacerbation.
    Lev-Tzion R; Focht G; Lujan R; Mendelovici A; Friss C; Greenfeld S; Kariv R; Ben-Tov A; Matz E; Nevo D; Barak-Corren Y; Dotan I; Turner D
    Clin Gastroenterol Hepatol; 2022 Jun; 20(6):e1263-e1282. PubMed ID: 34954338
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Beliefs, barriers and hesitancy towards the COVID-19 vaccine among Bangladeshi residents: Findings from a cross-sectional study.
    Hossain MS; Islam MS; Pardhan S; Banik R; Ahmed A; Islam MZ; Mahabub MS; Sikder MT
    PLoS One; 2022; 17(8):e0269944. PubMed ID: 35998135
    [TBL] [Abstract][Full Text] [Related]  

  • 28. SARS-CoV-2-inactivated vaccine hesitancy and the safety in inflammatory bowel disease patients: a single-center study.
    Cao Y; Feng J; Duan S; Yang Y; Zhang Y
    Therap Adv Gastroenterol; 2022; 15():17562848221101722. PubMed ID: 35706827
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Response to COVID-19 vaccine is reduced in patients with inflammatory bowel disease, but improved with additional dose.
    Shiga H; Kakuta Y; An K; Abe Y; Fujimaki S; Shimoyama Y; Naito T; Moroi R; Kuroha M; Khor SS; Kawai Y; Tokunaga K; Kinouchi Y; Masamune A
    J Gastroenterol Hepatol; 2023 Jan; 38(1):44-51. PubMed ID: 36066279
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antibody Response to SARS-CoV-2 Vaccination in Patients with Inflammatory Bowel Disease: Results of a Single-Center Cohort Study in a Tertiary Hospital in Germany.
    Classen JM; Muzalyova A; Nagl S; Fleischmann C; Ebigbo A; Römmele C; Messmann H; Schnoy E
    Dig Dis; 2022; 40(6):719-727. PubMed ID: 34915480
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety, hesitancy of coronavirus disease 2019 vaccination and pandemic burden in patients with inflammatory bowel disease: data of a national study (ESCAPE-IBD).
    Principi M; Macaluso FS; Todeschini A; Facciotti F; Contaldo A; Castiglione F; Nardone OM; Spagnuolo R; Doldo P; Riguccio G; Conforti FS; Viganò C; Ascolani M; Fiorino G; Correale C; Bodini G; Milla M; Scardino G; Vernero M; Desideri F; Caprioli F; Mannino M; Rizzo G; Orlando A;
    Eur J Gastroenterol Hepatol; 2023 Jun; 35(6):629-634. PubMed ID: 37115976
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Short-term outcome of pregnant women vaccinated with BNT162b2 mRNA COVID-19 vaccine.
    Bookstein Peretz S; Regev N; Novick L; Nachshol M; Goffer E; Ben-David A; Asraf K; Doolman R; Levin EG; Regev Yochay G; Yinon Y
    Ultrasound Obstet Gynecol; 2021 Sep; 58(3):450-456. PubMed ID: 34198360
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-SARS-CoV-2 Vaccination and Antibody Response in Patients With Inflammatory Bowel Disease on Immune-modifying Therapy: Prospective Single-Tertiary Study.
    Cerna K; Duricova D; Lukas M; Machkova N; Hruba V; Mitrova K; Kubickova K; Kostrejova M; Teplan V; Vasatko M; Kastylova K; Lukas M
    Inflamm Bowel Dis; 2022 Oct; 28(10):1506-1512. PubMed ID: 34849919
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Implementation and Short-term Adverse Events of Anti-SARS-CoV-2 Vaccines in Inflammatory Bowel Disease Patients: An International Web-based Survey.
    Ellul P; Revés J; Abreu B; Chaparro M; Gisbert JP; Allocca M; Fiorino G; Barberio B; Zingone F; Pisani A; Cassar D; Michalopoulos G; Mantzaris G; Koutroubakis I; Karmiris K; Katsanos K; Ďuricova D; Burisch J; Madsen GR; Maaser C; Naila A; Orfanoudaki E; Milivojevic V; Buisson A; Avedano L; Leone S; Torres J
    J Crohns Colitis; 2022 Aug; 16(7):1070-1078. PubMed ID: 35037033
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Young age, female sex, and presence of systemic adverse reactions are associated with high post-vaccination antibody titer after two doses of BNT162b2 mRNA SARS-CoV-2 vaccination: An observational study of 646 Japanese healthcare workers and university staff.
    Uwamino Y; Kurafuji T; Sato Y; Tomita Y; Shibata A; Tanabe A; Yatabe Y; Noguchi M; Arai T; Ohno A; Yokota H; Yamasawa W; Uno S; Nishimura T; Hasegawa N; Saya H; Wakui M; Murata M;
    Vaccine; 2022 Feb; 40(7):1019-1025. PubMed ID: 35033389
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety of SARS-CoV-2 vaccination in patients with inflammatory bowel disease: A systematic review and meta-analysis.
    James D; Jena A; Bharath PN; Choudhury A; Singh AK; Sebastian S; Sharma V
    Dig Liver Dis; 2022 Jun; 54(6):713-721. PubMed ID: 35382972
    [TBL] [Abstract][Full Text] [Related]  

  • 37. COVID-19 vaccination side effects among the child age group: a large cross-sectional online based survey in Saudi Arabia.
    Alwafi H; Naser AY; Aldhahir AM; Alhazmi A; Alosaimi AN; Mandili RA; Majeed Z; Salawati E; Ekram R; Samannodi M; Assaggaf H; Almatrafi M; Alqahtani JS; Alsanosi SM; Minshawi F
    BMC Infect Dis; 2022 Dec; 22(1):911. PubMed ID: 36474174
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Postmarketing active surveillance of myocarditis and pericarditis following vaccination with COVID-19 mRNA vaccines in persons aged 12 to 39 years in Italy: A multi-database, self-controlled case series study.
    Massari M; Spila Alegiani S; Morciano C; Spuri M; Marchione P; Felicetti P; Belleudi V; Poggi FR; Lazzeretti M; Ercolanoni M; Clagnan E; Bovo E; Trifirò G; Moretti U; Monaco G; Leoni O; Da Cas R; Petronzelli F; Tartaglia L; Mores N; Zanoni G; Rossi P; Samez S; Zappetti C; Marra AR; Menniti Ippolito F;
    PLoS Med; 2022 Jul; 19(7):e1004056. PubMed ID: 35900992
    [TBL] [Abstract][Full Text] [Related]  

  • 39. SARS-CoV-2 vaccination for patients with inflammatory bowel disease: a British Society of Gastroenterology Inflammatory Bowel Disease section and IBD Clinical Research Group position statement.
    Alexander JL; Moran GW; Gaya DR; Raine T; Hart A; Kennedy NA; Lindsay JO; MacDonald J; Segal JP; Sebastian S; Selinger CP; Parkes M; Smith PJ; Dhar A; Subramanian S; Arasaradnam R; Lamb CA; Ahmad T; Lees CW; Dobson L; Wakeman R; Iqbal TH; Arnott I; Powell N;
    Lancet Gastroenterol Hepatol; 2021 Mar; 6(3):218-224. PubMed ID: 33508241
    [TBL] [Abstract][Full Text] [Related]  

  • 40. BNT162b2 mRNA COVID-19 vaccine is safe in a setting of patients on biologic therapy with inflammatory bowel diseases: a monocentric real-life study.
    Pellegrino R; Pellino G; Selvaggi L; Selvaggi F; Federico A; Romano M; Gravina AG
    Expert Rev Clin Pharmacol; 2022 Oct; 15(10):1243-1252. PubMed ID: 36047032
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.